Biodexa Pharmaceuticals Plc Stock London S.E.
Equities
BDRX
GB00BNGF1L75
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.58M 5.72M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.92% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 19-09-08 |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 44 | 21-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 22-06-19 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 14-10-28 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 19-09-08 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |